Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Vaccinex Inc (VCNX)

Vaccinex Inc (VCNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vaccinex, Inc. Reports Q3 Financial Results and Advances Alzheimer’s Development While Exploring Partnership Opportunities Quiver Quantitative, Inc. - Mon Nov 18, 5:52PM CST

Vaccinex reports promising Alzheimer’s treatment results, financial updates, and plans for partnerships to enhance development.Quiver AI SummaryVaccinex, Inc. has reported its financial results for the...

VCNX : 3.11 (-1.58%)
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire - Mon Nov 18, 7:30AM CST

VCNX : 3.11 (-1.58%)
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC GlobeNewswire - Thu Nov 7, 7:30AM CST

VCNX : 3.11 (-1.58%)
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting GlobeNewswire - Tue Nov 5, 7:30AM CST

VCNX : 3.11 (-1.58%)
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain GlobeNewswire - Thu Oct 31, 9:00AM CDT

VCNX : 3.11 (-1.58%)
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024 GlobeNewswire - Thu Oct 24, 7:30AM CDT

VCNX : 3.11 (-1.58%)
MarketBeat Week in Review – 2/6 - 2/10 MarketBeat - Sat Feb 11, 2023

Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely

AI : 26.54 (+2.12%)
BBAI : 1.7600 (+3.53%)
PLTR : 61.26 (-6.86%)
SOUN : 6.19 (-2.67%)
MSFT : 415.76 (+0.18%)
ON : 66.48 (+2.66%)
AAPL : 228.02 (+1.34%)
AMZN : 201.70 (-0.45%)
TTWO : 182.93 (+2.99%)
MRK : 96.56 (+0.26%)
VCNX : 3.11 (-1.58%)
ENPH : 62.40 (+4.84%)
Author
Should Investors Buy or Sell the Vaccinex Patent News? MarketBeat - Tue Feb 7, 2023

Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?

VCNX : 3.11 (-1.58%)
MRK : 96.56 (+0.26%)
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation Globe Newswire - Mon Aug 8, 2022

Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other...

VCNX : 3.11 (-1.58%)
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease Globe Newswire - Fri Jul 29, 2022

ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated...

VCNX : 3.11 (-1.58%)

Barchart Exclusives

Is It Time to Buy This Dividend Stock With Nuclear Energy Upside? Barchart - Mon Nov 18, 6:30PM CST
Apart from its prowess in nuclear energy, this energy company is also deploying AI. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot